Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Galy Co. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These 2 pending office actions suggest an active prosecution pipeline. The company is currently navigating these requests within a specific regulatory and technical environment. The data shows that prosecution is handled by 1 distinct examiner, STANKOVIC, BRATISLAV.
This examiner is the busiest examiner for the company, holding 2 busiest examiner pending actions. Despite having multiple actions, they are all contained within 1 distinct art unit, indicating that Galy Co. is focusing its Biotechnology & Pharmaceuticals efforts on a specific technological niche. Because 1 distinct examiner is responsible for the 2 pending office actions, the applicant can expect a consistent examination style across their pending matters. The 2 busiest examiner pending actions are under the authority of STANKOVIC, BRATISLAV.
The concentration in 1 distinct art unit means that the 2 pending office actions will likely be evaluated under the same set of internal guidelines. This allows for a unified response strategy for the 2 pending office actions. Practitioners can leverage the consistency of having 1 distinct examiner to streamline their arguments. This approach reduces the complexity of managing the 2 pending office actions, as there is no need to account for different examiner behaviors or art unit standards.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STANKOVIC, BRATISLAV | 2 | 70.0% | +21.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033957 | CELL LINES, VARIETIES, AND METHODS FOR IN VITRO COTTON FIBER PRODUCTION | STANKOVIC, BRATISLAV | 12d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18272488 | CELL LINES, VARIETIES, AND METHODS FOR IN VITRO COTTON FIBER PRODUCTION | STANKOVIC, BRATISLAV | 4d overdue |
| 18033957 | CELL LINES, VARIETIES, AND METHODS FOR IN VITRO COTTON FIBER PRODUCTION | STANKOVIC, BRATISLAV | 12d |
| Art Unit | Apps |
|---|---|
| 1662 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18272488 | CELL LINES, VARIETIES, AND METHODS FOR IN VITRO COTTON FIBER PRODUCTION | STANKOVIC, BRATISLAV | 1662 | §103Other | Final Rejection | 4d overdue | Pending | Jul 14, 2023 |
| 18033957 | CELL LINES, VARIETIES, AND METHODS FOR IN VITRO COTTON FIBER PRODUCTION | STANKOVIC, BRATISLAV | 1662 | §103§112 | Non-Final OA | 12d | Pending | Apr 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial